HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Liquid biopsies have emerged as a transformative tool in cancer research, offering a less invasive alternative to traditional tissue biopsies for detecting cancer-related genetic mutations. Liquid biopsies analyze blood, urine, or other bodily fluids for cancer biomarkers, such as circulating tumor DNA (ctDNA), which can provide early signs of cancer. This technology has revolutionized cancer monitoring by enabling doctors to track a patient’s response to treatment and detect recurrence before clinical symptoms appear. Liquid biopsies are also being explored for their potential to detect minimal residual disease, providing valuable insights into the effectiveness of treatments and guiding personalized care strategies for patients.
